Off the wire
• U.S. stocks tumble on soft data  • Wall Street bonus rises in 2014  • 26 Iraqi soldiers killed in clashes with IS  • Barcelona president, his predecessor and the club itself to face trail for fraud  • Paris-Nice cycling fifth stage results  • Xinhua Asia-Pacific news summary at 1600 GMT, March 13  • WHO to host first ministerial conference on global action against dementia  • Ethiopian runner triumphs in Jerusalem international marathon  • Ferrari quick, Mercedes dominant in Australian GP practice  • Greek statistical authority revises up 2014 GDP growth to 0.8 pct  
You are here: 　 Home

Anti-herpes drug may help treat HIV: study

Xinhua, March 14, 2015 Adjust font size:

Valacyclovir, a drug commonly used to treat genital herpes, may help reduce the levels of HIV, the virus that causes AIDS, even when patients do not have herpes, a study suggested Friday.

"These findings are very encouraging," said senior author Leonid Margolis, head of the Section on Intercellular Interactions at the National Institute of Child Health and Human Development ( NICHD), part the of the U.S. National Institutes of Health.

"If valacyclovir's effectiveness against HIV can be confirmed in a larger cohort, it could be added to the mix of drugs used to suppress the virus, and might prove especially helpful in cases in which HIV has developed resistance to other drugs," Margolis said.

The study, published online in the British journal Clinical Infectious Diseases, was conducted by researchers from the NICHD, Case Western Reserve University, Emory University, and the Civic Association for Health and Education in Peru.

Earlier studies have shown that valacyclovir reduces HIV levels in patients coinfected with HIV and herpes simplex virus 2 (HSV-2), the virus that causes genital herpes.

Previously, this effect has been attributed to the drug's anti- HSV-2 activity, which then results in fewer active immune cells for HIV to infect.

Yet, the new study indicated that the drug likely reduced HIV levels by interfering directly with HIV's reproductive machinery and did not require the presence of HSV-2.

According to the researchers, HSV-2 chemically alters valacyclovir, by attaching chemical groups known as phosphates to it, resulting in an altered form of the drug that suppresses HSV-2.

They believed that this form also interferes with HIV's ability to reproduce.

In the new study, researchers enrolled 18 HIV-infected patients, none of whom were infected with HSV-2, and treated them with valacyclovir.

Half of the patients took valacyclovir twice a day for 12 weeks, while the other half received a placebo. After two weeks, the placebo group received valacyclovir while the group originally treated with the drug switched to the placebo.

When the patients took valacyclovir, their blood HIV levels declined significantly, and when they took the placebo, their HIV levels went up.

Given the ability of the drug to lower HIV levels, the researchers believed that valacyclovir could one day be added to the cocktail of drugs given to HIV-infected people. Endite